Glenmark introduces Zanubrutinib, a novel cancer treatment, to the Indian market
Glenmark Pharmaceuticals, a renowned drug company, has announced its plan to launch a cancer treatment drug called zanubrutinib, also known as Brukinsa, in India. The drug has been approved by the Drugs Controller General of India (DCGI) and will be used to treat five special B-cell malignancies, including chronic lymphocytic leukemia, Waldenstrom macroglobulinemia, mantle cell lymphoma, marginal zone lymphoma, and follicular lymphoma. This makes it the first and only Bruton’s tyrosine kinase (BTK) inhibitor to be legitimized in India for these treatments.
The drug has already been approved for use in over 60 countries, including major markets like the United States, China, the European Union, and Canada. Zanubrutinib works by blocking the action of unhealthy proteins that signal cancer cells to multiply, helping to stop the spread of cancer cells. It is classified as a tyrosine kinase inhibitor (TKI) and specifically targets the protein Bruton’s tyrosine kinase, making it a Bruton tyrosine kinase inhibitor (BTKi).
Glenmark Pharmaceuticals has a history of innovative drug launches, including a medication for glycemic control and weight loss for diabetes patients, called Empagliflozin, under the brand name Glempa. The company has also launched fixed-dose combinations of Empagliflozin, which have been shown to improve glycemic control, aid in weight loss, and reduce cardiovascular outcomes in patients with type 2 diabetes mellitus.
The launch of zanubrutinib in India marks a significant milestone in Glenmark’s innovative oncology portfolio and offers patients in India access to a globally trusted therapy with proven efficacy and safety. Alok Malik, President and Business Head of Glenmark Pharmaceuticals, expressed the company’s enthusiasm for bringing Brukinsa to India, stating that it will be a significant addition to their innovative oncology portfolio.
The introduction of zanubrutinib in India is expected to change the face of cancer treatment in the country, offering new hope and possibilities for patients. With its proven efficacy and safety, the drug has the potential to make a significant impact on the lives of those affected by cancer. As Glenmark continues to innovate and expand its portfolio, the company remains committed to providing access to globally trusted therapies and improving the lives of patients in India and around the world.
Empowering female professionals to navigate and succeed in the life sciences industry
BioWISE, a pioneering initiative, aims to empower women entering the STEM workforce, particularly in the life sciences sector. This multi-dimensional platform seeks to bridge the gap in representation and opportunities for women in science, technology, engineering, and mathematics fields. By providing a comprehensive framework for building competencies, fostering mentorship, and opening up research and industry pathways, BioWISE is poised to make a significant impact on the scientific ecosystem.
The initiative is made possible through a collaborative effort between Biocon Foundation, which will provide funding, and industry partner Biocon Biologics, whose experts will offer mentorship and guidance. The National Centre for Biological Sciences (NCBS) will serve as the host institute and academic mentoring partner, lending its expertise and resources to the program. Additionally, the BeST Cluster will contribute to the design, management, and implementation of BioWISE, ensuring a well-rounded and effective approach.
At the heart of BioWISE is a commitment to diversity, inclusivity, and equity. The program will support 25 women students from diverse communities, providing them with the tools and opportunities necessary to succeed in the life sciences workforce. By doing so, BioWISE aims to create a more representative and vibrant scientific ecosystem. As Kiran Mazumdar-Shaw, Chairperson of the Biocon Group, noted, this initiative is a significant step towards building a more diverse and inclusive scientific community.
The benefits of BioWISE are multifaceted. By providing women with access to mentorship, research opportunities, and industry pathways, the program can help address the underrepresentation of women in STEM fields. Moreover, by fostering a culture of inclusivity and equity, BioWISE can contribute to a more vibrant and dynamic scientific ecosystem, where diverse perspectives and ideas can thrive. Ultimately, the success of BioWISE can have far-reaching implications, inspiring a new generation of women to pursue careers in science and helping to drive innovation and progress in the life sciences sector.
Apollo Cradle and Children’s Hospital, headquartered in Hyderabad, is poised for substantial growth with plans to launch 7-8 new facilities over the next five years. – TRIPURA STAR NEWS
Apollo Cradle and Children’s Hospital, a prominent healthcare provider, has announced plans for significant expansion in the next five years. Headquartered in Hyderabad, the hospital aims to set up 7-8 new centers across the country, catering to the growing demand for quality healthcare services. This expansion plan is a testament to the hospital’s commitment to providing world-class medical care to patients, particularly in the fields of obstetrics, gynecology, pediatrics, and fertility.
Apollo Cradle and Children’s Hospital has established itself as a trusted brand in the healthcare industry, with a strong presence in major cities such as Hyderabad, Bengaluru, and Chennai. The hospital’s state-of-the-art facilities, cutting-edge technology, and team of experienced medical professionals have earned it a reputation for delivering exceptional patient care. The proposed expansion will enable the hospital to extend its services to more patients, addressing the shortage of quality healthcare facilities in various regions.
The expansion plan is expected to create new job opportunities in the healthcare sector, with the hospital planning to recruit talented medical professionals, nurses, and support staff. This will not only boost the local economy but also contribute to the growth of the healthcare industry as a whole. The hospital’s commitment to providing comprehensive healthcare services, including prenatal care, pregnancy care, and pediatric care, will help bridge the gap in healthcare services, particularly in rural and semi-urban areas.
The hospital’s management has identified key locations for the new centers, focusing on areas with limited access to quality healthcare facilities. The expansion plan will be implemented in a phased manner, with the hospital expected to invest significantly in infrastructure development, technology upgradation, and talent acquisition. The new centers will be designed to provide a wide range of medical services, including obstetrics, gynecology, pediatrics, fertility, and neonatology, ensuring that patients have access to comprehensive healthcare solutions under one roof.
In conclusion, Apollo Cradle and Children’s Hospital’s expansion plan is a significant development in the healthcare industry, with the potential to transform the lives of millions of patients across the country. With its commitment to delivering world-class healthcare services, the hospital is poised to become a leading player in the industry, setting new benchmarks for quality, accessibility, and affordability. As the hospital embarks on this ambitious expansion plan, it is expected to make a positive impact on the healthcare landscape, contributing to the well-being of patients and the growth of the healthcare sector as a whole.
Agenus and Zydus Lifesciences have formed a $141 million partnership to increase availability of Botensilimab and Balstilimab.
Agenus Inc., a clinical-stage immuno-oncology company, has partnered with Zydus Lifesciences, a global healthcare company, in a $141 million deal to expand access to its investigational therapies, botensilimab and balstilimab. This partnership aims to accelerate the development and commercialization of these innovative treatments, bringing new hope to patients with various types of cancer.
Botensilimab is a novel, bispecific antibody that targets two immune checkpoints, CTLA-4 and PD-1, which are known to play a crucial role in cancer progression. Balstilimab, on the other hand, is a monoclonal antibody that targets PD-1. Both therapies have shown promising results in early clinical trials, demonstrating significant anti-tumor activity and a favorable safety profile.
Under the terms of the agreement, Zydus Lifesciences will acquire the rights to develop and commercialize botensilimab and balstilimab in India and other emerging markets. Agenus will retain the rights to develop and commercialize these therapies in the United States, Europe, and other developed markets. The partnership will enable the companies to pool their resources, expertise, and networks to accelerate the development of these therapies and make them more widely available to patients.
The deal includes an upfront payment of $15 million, with additional milestone payments of up to $126 million contingent on the achievement of certain regulatory and commercial milestones. Agenus will also be eligible to receive royalties on net sales of botensilimab and balstilimab in Zydus Lifesciences’ territories.
This partnership is a significant milestone for Agenus, as it marks the company’s entry into emerging markets and demonstrates the value of its innovative pipeline. The collaboration with Zydus Lifesciences will enable Agenus to tap into the growing demand for cancer treatments in these markets, while also gaining access to Zydus Lifesciences’ extensive network and expertise in these regions.
The partnership is also a testament to the growing importance of immuno-oncology therapies in the treatment of cancer. As the field continues to evolve, companies like Agenus and Zydus Lifesciences are at the forefront of developing innovative treatments that have the potential to transform patient outcomes. With this partnership, both companies are well-positioned to make a meaningful impact in the lives of patients with cancer, and to contribute to the advancement of cancer research and treatment.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.